Medicus Pharma Stock Soars 12.08% on Public Offering

Medicus Pharma's stock surged by 12.08% in pre-market trading on June 4, 2025, marking a significant rise in investor confidence.

Medicus Pharma recently closed a $7.0 million public offering, which included the sale of 2,260,000 units at $3.10 per unit. Each unit comprises one common share and a warrant to purchase an additional share at a later date. The proceeds from this offering are earmarked to fund the company's Phase 2 proof of concept clinical trial for the treatment of basal cell carcinoma.

Despite the successful funding round, Medicus Pharma's stock experienced a notable decline of nearly 29% earlier in the day. This volatility can be attributed to market reactions to the public offering and the subsequent dilution of shares. Investors are closely monitoring the company's progress in its clinical trials, as the outcomes will significantly impact its future valuation and market position.